January 2020 News & Views. Read articles on: AMCP Releases Format for Formulary Submissions, Version 4.1; 2020-2021 AMCP Board of Directors Announced; CEO Cantrell Previews 2020 Priorities; AMCP Forum Seeks Modernized Specialty Drug Benefits; JMCP Marks 25th Anniversary in 2020; Members in Florida Establish Latest AMCP Affiliate; Legislative Days Student Scholarship; AMCP 2020 to Present Six Education Tracks Covering Hottest Topics
AMCP CEO Blog: As a new decade dawns, AMCP is preparing for the twists and turns of an uncertain first year. With health care a top issue in this year’s presidential campaigns, drug pricing a favorite target, and biosimilar use poised to expand, seeing where this year will lead requires much more than “2020” vision.
AMCP has released Version 4.1 of the AMCP Format for Formulary Submissions, which includes two new dossier types for biopharmaceutical manufacturers to share evidence on unapproved products and new indications that are under review by the U.S. Food and Drug Administration (FDA).
The Academy of Managed Care Pharmacy (AMCP) thanks the Office of Inspector General (OIG) for the opportunity to provide written comments regarding the new proposed rulemaking on “Medicare and State Healthcare Programs: Fraud and Abuse; Revisions to Safe Harbors Under the Anti-Kickback Statute, and Civil Monetary Penalty Rules Regarding Beneficiary Inducements” published in the Federal Register on October 17, 2019.
Trump Administration Issues Proposed Rule Allowing Importation; House Passes H.R. 3 Drug Pricing Bill on Party-Line Vote; AMCP Submits Letter to House on 21st Century Cures 2.0; Stephen Hahn, MD, Confirmed as New FDA Commissioner; FDA Issues Draft Guidance on Interchangeable Insulin
December 2019 News & Views: Read articles on CEO Blog: AMCP Defining Digital Therapeutics for Coverage, USC School of Pharmacy Wins AMCP Chapter of the Year Award, AMCP Foundation Honors Best Posters at Nexus 2019
Partnership Forum: This forum made recommendations and considerations for ways that benefit design and reimbursement may evolve without compromising patient access and care.